RARE vs REPL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RARE · Ultragenyx Pharmaceutical$16.48 ▼ 4.30%
REPL · Replimune$19.07 ▼ 0.83%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RARE -49.7%
- REPL +103.1%
Head to head
| Metric | RARE | REPL |
|---|---|---|
| Price | $16.48 | $19.07 |
| Change today | ▼ 4.30% | ▼ 0.83% |
| Market cap | $1.68B | $1.81B |
| Return, 3 months | -35.9% | +29.6% |
| Return, year to date | -28.3% | +96.2% |
| Return, 1 year | -50.9% | +107.3% |
| P/E (TTM) | – | – |
| P/B | -4.5 | 8.8 |
| P/E percentile vs own 5y | 96th | 17th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +8.1% | – |
| Net profit growth (YoY) | +34.4% | +31.3% |
| Gross margin | 82.9% | – |
| Operating margin | -64.0% | – |
| Net margin | -71.8% | – |
| Return on equity | – | -115.8% |
| Analyst target vs. price | +54.1% | +25.9% |
| Analyst buy share | 47% | 100% |
| RSI (14) | 51 | 54 |
| 30-day volatility | 58.7% | 99.2% |
| Max drawdown, 1 year | -64.8% | -84.2% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- REPL is the largest of the group by market value.
- REPL has returned the most over the past year.
- RARE has been the calmest stock over the last 30 days.